Nexalin Technology (NXL) Cash & Equivalents Growth (1y) (2022 - 2026)
Nexalin Technology (NXL) Cash & Equivalents Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | -26.57% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 42.78% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 0.94% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -11.19% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | -4.66% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | -44.03% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 19.49% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 72.43% |
| 10 | Nexalin Technology | 6.98 Mn | 5.97 Mn | 8,897.00 | -81.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -81.26% |
| Mar 31, 2026 | 94.19% |
| Dec 31, 2025 | 434.12% |
| Sep 30, 2025 | -86.92% |
| Jun 30, 2025 | -49.18% |
| Mar 31, 2025 | -61.07% |
| Dec 31, 2024 | -0.99% |
| Sep 30, 2024 | 26.19% |
| Jun 30, 2024 | -80.99% |
| Mar 31, 2024 | -69.84% |
| Dec 31, 2023 | 256.53% |
| Sep 30, 2023 | -54.53% |
| Dec 31, 2022 | -75.41% |